Origenis Gmbh
A Germany-based small-molecule drug discovery company that applies AI-driven design, automated synthesis, and microscale property testing to generate preclinical development candidates focused on CNS, ophthalmology, oncology and antiviral indications. The organization integrates in-silico design, patent analytics, and wet-lab validation in an iterative workflow and collaborates with external partners and spin-out entities for clinical progression.
Industries
N/A
Nr. of Employees
small (1-50)
Origenis Gmbh
Patents
1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
US-12384788-B2
View Details
1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
US-12384788-B2
View DetailsProducts
Preclinical small-molecule pipelines (neurodegeneration, brain cancer, leaky BBB, antivirals, ophthalmology)
Series of preclinical candidate programs focused on targets and molecules designed for difficult-to-reach tissues (brain, eye) and other indications; includes lead optimization and PK evaluation.
Platform components: design engine, synthesis execution, patent analytics, microscale property testing
Modular platform functions enabling design, automated synthesis, patent assessment, and early tissue-distribution testing that together support discovery programs.
Preclinical small-molecule pipelines (neurodegeneration, brain cancer, leaky BBB, antivirals, ophthalmology)
Series of preclinical candidate programs focused on targets and molecules designed for difficult-to-reach tissues (brain, eye) and other indications; includes lead optimization and PK evaluation.
Platform components: design engine, synthesis execution, patent analytics, microscale property testing
Modular platform functions enabling design, automated synthesis, patent assessment, and early tissue-distribution testing that together support discovery programs.
Services
In-silico target and compound design, synthesizability assessment, and prioritization of preclinical candidates for client programs.
Execution of computationally planned syntheses and generation of experimental physicochemical and biological data to validate candidates.
Continuous patent surveillance and novelty assessment using a proprietary patent analytics database covering patents since 1970.
In-silico target and compound design, synthesizability assessment, and prioritization of preclinical candidates for client programs.
Execution of computationally planned syntheses and generation of experimental physicochemical and biological data to validate candidates.
Continuous patent surveillance and novelty assessment using a proprietary patent analytics database covering patents since 1970.
Expertise Areas
- AI-driven small-molecule drug discovery
- CNS drug development and blood-brain-barrier optimization
- Ophthalmic drug design for topical and systemic delivery
- Preclinical candidate optimization and PK/PD
Key Technologies
- Machine learning and evolutionary algorithms for molecular design
- Large-scale virtual screening of ultra-large chemical spaces
- Automated synthesis workflows
- Patent text-mining and analytics
News & Updates
Participation/attendance at BIO International Convention (San Diego).
Attendance at AACR Annual Meeting 2024.
Attendance at ASCO 2024 (oncology conference).
Participation in BIO CEO & Investor Conference.
Participation at BIO-Europe 2023.
Peer-reviewed article reporting work toward new AQP4 inhibitors (Int. J. Mol. Sci., 2024).
Participation/attendance at BIO International Convention (San Diego).
Attendance at AACR Annual Meeting 2024.
Attendance at ASCO 2024 (oncology conference).
Participation in BIO CEO & Investor Conference.
Participation at BIO-Europe 2023.
Peer-reviewed article reporting work toward new AQP4 inhibitors (Int. J. Mol. Sci., 2024).